Plasma cell-free DNA and circulating tumor cells as prognostic biomarkers in small cell lung cancer patients.

ABSTRACT:

Background

Lack of biomarkers for treatment selection and monitoring in small cell lung cancer (SCLC) patients with the limited therapeutic options, result in poor outcomes. Therefore, new prognostic biomarkers are needed to improve their management. The prognostic value of cell-free DNA (cfDNA) and circulating tumor cells (CTCs) have been less explored in SCLC.

Methods

We quantified cfDNA in 46 SCLC patients at different times during first-line of chemotherapy or chemo-immunotherapy. Moreover, CTCs were analyzed in 21 patients before therapy onset using CellSearch^® system. The possible association between both biomarkers and patients' outcomes was investigated in order to develop a prognostic model.

Results

High cfDNA levels before therapy were associated

SUBMITTER: Mondelo-Macia P 

PROVIDER: S-EPMC9641037 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature